<?xml version='1.0' encoding='UTF-8'?><?xml-stylesheet href='static/style.xsl' type='text/xsl'?><OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd"><responseDate>2026-11-22T10:24:30Z</responseDate><request verb="GetRecord" identifier="oai:ecommons.cornell.edu:1813/116507" metadataPrefix="dim">https://ecommons.cornell.edu/server/oai/request</request><GetRecord><record><header><identifier>oai:ecommons.cornell.edu:1813/116507</identifier><datestamp>2026-05-15T19:47:40Z</datestamp><setSpec>com_1813_35</setSpec><setSpec>col_1813_47</setSpec></header><metadata><dim:dim xmlns:dim="http://www.dspace.org/xmlns/dspace/dim" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:doc="http://www.lyncode.com/xoai" xsi:schemaLocation="http://www.dspace.org/xmlns/dspace/dim http://www.dspace.org/schema/dim.xsd">
   <dim:field mdschema="dc" element="contributor" qualifier="author">Li, Yitong</dim:field>
   <dim:field mdschema="dc" element="contributor" qualifier="chair" lang="en_US">Liu, Rui</dim:field>
   <dim:field mdschema="dc" element="contributor" qualifier="committeeMember" lang="en_US">Brenna, James</dim:field>
   <dim:field mdschema="dc" element="contributor" qualifier="committeeMember" lang="en_US">Glahn, Raymond</dim:field>
   <dim:field mdschema="dc" element="date" qualifier="accessioned">2025-01-14T19:59:59Z</dim:field>
   <dim:field mdschema="dc" element="date" qualifier="issued">2024-08</dim:field>
   <dim:field mdschema="dc" element="identifier" qualifier="other">ProQuest Submission ID: 14437</dim:field>
   <dim:field mdschema="dc" element="identifier" qualifier="other">ProQuest Publication ID: 31481873</dim:field>
   <dim:field mdschema="dc" element="identifier" qualifier="uri">https://hdl.handle.net/1813/116507</dim:field>
   <dim:field mdschema="dc" element="identifier" qualifier="doi">https://doi.org/10.7298/sr7y-r402</dim:field>
   <dim:field mdschema="dc" element="identifier" qualifier="bibid">16611716</dim:field>
   <dim:field mdschema="dc" element="description" lang="en_US">159 pages</dim:field>
   <dim:field mdschema="dc" element="description" qualifier="abstract" lang="en_US">Metabolic syndrome (MetS) is a prevalent and multifaceted disorder characterized by the clustering of metabolic abnormalities, including insulin resistance, dyslipidemia, obesity, and chronic inflammation. These interconnected pathologies significantly increase the risk of developing life-threatening conditions like cardiovascular disease, type 2 diabetes, and metabolic dysfunction-associated fatty liver disease (MAFLD). The high prevalence of MetS is largely attributable to the overconsumption of nutrients associated with urban lifestyles. Consequently, there is an urgent need to explore therapeutic strategies addressing dietary interventions that can simultaneously target multiple aspects of MetS. Phenolic compounds, abundant in whole grains and medicinal plants, have garnered significant attention for their potential to combat metabolic diseases due to their antioxidant, anti-inflammatory, and metabolic regulatory properties. Our research aimed to elucidate the therapeutic effects of ferulic acid (FA), a prominent phenolic compound, on various pathological features of MetS using the palmitate-treated HepG2 hepatic cell line as an in vitro model. Our findings demonstrate that FA ameliorates insulin resistance, dyslipidemia, and gluconeogenesis by modulating the insulin/IGF-1 receptor/PI3K/AKT signaling pathway, thereby improving glucose and lipid metabolism. Additionally, FA counteracts mitochondrial dysfunction and impaired autophagy by restoring mitochondrial dynamics and promoting autophagic flux through the AMPK signaling pathway, ensuring cellular homeostasis. Notably, FA also regulates cell cycle progression and inflammation by inhibiting NF-κB signaling, reducing pro-inflammatory cytokine production, and regulating cell cycle-related proteins, thus mitigating palmitate-induced G1 cell cycle arrest and chronic inflammation. These multifaceted effects underscore FA's therapeutic potential in preventing and combating MetS.</dim:field>
   <dim:field mdschema="dc" element="description" qualifier="embargo">2026-09-03</dim:field>
   <dim:field mdschema="dc" element="language" qualifier="iso">en</dim:field>
   <dim:field mdschema="dc" element="subject" lang="en_US">diabetes</dim:field>
   <dim:field mdschema="dc" element="subject" lang="en_US">ferulic acid</dim:field>
   <dim:field mdschema="dc" element="subject" lang="en_US">metabolic syndrome</dim:field>
   <dim:field mdschema="dc" element="subject" lang="en_US">obesity</dim:field>
   <dim:field mdschema="dc" element="subject" lang="en_US">phenolics</dim:field>
   <dim:field mdschema="dc" element="subject" lang="en_US">whole grain</dim:field>
   <dim:field mdschema="dc" element="title" lang="en_US">FERULIC ACID AS A POTENTIAL THERAPEUTICAL AGENT IN METABOLIC SYNDROME PREVENTION-MOLECULAR MECHANISM OF ACTION</dim:field>
   <dim:field mdschema="dc" element="type" lang="en_US">dissertation or thesis</dim:field>
   <dim:field mdschema="dc" element="relation" qualifier="localuri">https://newcatalog.library.cornell.edu/catalog/16611716</dim:field>
   <dim:field mdschema="dc" element="format" qualifier="mimetype">application/pdf</dim:field>
   <dim:field mdschema="thesis" element="degree" qualifier="discipline">Food Science and Technology</dim:field>
   <dim:field mdschema="thesis" element="degree" qualifier="grantor">Cornell University</dim:field>
   <dim:field mdschema="thesis" element="degree" qualifier="level">Doctor of Philosophy</dim:field>
   <dim:field mdschema="thesis" element="degree" qualifier="name">Ph. D., Food Science and Technology</dim:field>
   <dim:field mdschema="dcterms" element="license">https://hdl.handle.net/1813/59810.2</dim:field>
   <dim:field mdschema="dspace" element="entity" qualifier="type">Publication</dim:field>
   <dim:field mdschema="cris" element="virtual" qualifier="collection" authority="https://cornell-ecommons.eks.prod.4science.cloud/handle/1813/47" confidence="600">Cornell Theses and Dissertations</dim:field>
   <dim:field mdschema="cris" element="virtual" qualifier="author">Li, Yitong</dim:field>
   <dim:field mdschema="cris" element="virtualsource" qualifier="collection">5893a6ea-7af3-41d7-abc6-04bcd26ab5df</dim:field>
   <dim:field mdschema="others" element="access-status">embargo</dim:field>
   <dim:field mdschema="others" element="access-status">embargo</dim:field>
   <dim:field mdschema="cerif" element="openaire" authority="" confidence="-1">&lt;Publication xmlns="https://www.openaire.eu/cerif-profile/1.1/" id="1d57162b-06ad-4dd0-8f4b-45388bc85e9e">
	&lt;Type xmlns="https://www.openaire.eu/cerif-profile/vocab/COAR_Publication_Types">http://purl.org/coar/resource_type/c_1843&lt;/Type>
	&lt;Language>en&lt;/Language>
   	&lt;Title>FERULIC ACID AS A POTENTIAL THERAPEUTICAL AGENT IN METABOLIC SYNDROME PREVENTION-MOLECULAR MECHANISM OF ACTION&lt;/Title>
   	&lt;PublishedIn>
    	&lt;Publication>
      	&lt;/Publication>
   	&lt;/PublishedIn>
   	&lt;PublicationDate>2024-08&lt;/PublicationDate>
   	&lt;DOI>https://doi.org/10.7298/sr7y-r402&lt;/DOI>
   	&lt;Authors>
      	&lt;Author>
        	&lt;DisplayName>Li, Yitong&lt;/DisplayName>
         	&lt;Affiliation>
         		&lt;OrgUnit>
         		&lt;/OrgUnit>
         	&lt;/Affiliation>
      	&lt;/Author>
	&lt;/Authors>
   	&lt;Editors>
	&lt;/Editors>
    &lt;Publishers>
        &lt;Publisher>
            &lt;OrgUnit />
        &lt;/Publisher>
    &lt;/Publishers>
    &lt;Keyword>diabetes&lt;/Keyword>
    &lt;Keyword>ferulic acid&lt;/Keyword>
    &lt;Keyword>metabolic syndrome&lt;/Keyword>
    &lt;Keyword>obesity&lt;/Keyword>
    &lt;Keyword>phenolics&lt;/Keyword>
    &lt;Keyword>whole grain&lt;/Keyword>
   	&lt;Abstract>Metabolic syndrome (MetS) is a prevalent and multifaceted disorder characterized by the clustering of metabolic abnormalities, including insulin resistance, dyslipidemia, obesity, and chronic inflammation. These interconnected pathologies significantly increase the risk of developing life-threatening conditions like cardiovascular disease, type 2 diabetes, and metabolic dysfunction-associated fatty liver disease (MAFLD). The high prevalence of MetS is largely attributable to the overconsumption of nutrients associated with urban lifestyles. Consequently, there is an urgent need to explore therapeutic strategies addressing dietary interventions that can simultaneously target multiple aspects of MetS. Phenolic compounds, abundant in whole grains and medicinal plants, have garnered significant attention for their potential to combat metabolic diseases due to their antioxidant, anti-inflammatory, and metabolic regulatory properties. Our research aimed to elucidate the therapeutic effects of ferulic acid (FA), a prominent phenolic compound, on various pathological features of MetS using the palmitate-treated HepG2 hepatic cell line as an in vitro model. Our findings demonstrate that FA ameliorates insulin resistance, dyslipidemia, and gluconeogenesis by modulating the insulin/IGF-1 receptor/PI3K/AKT signaling pathway, thereby improving glucose and lipid metabolism. Additionally, FA counteracts mitochondrial dysfunction and impaired autophagy by restoring mitochondrial dynamics and promoting autophagic flux through the AMPK signaling pathway, ensuring cellular homeostasis. Notably, FA also regulates cell cycle progression and inflammation by inhibiting NF-κB signaling, reducing pro-inflammatory cytokine production, and regulating cell cycle-related proteins, thus mitigating palmitate-induced G1 cell cycle arrest and chronic inflammation. These multifaceted effects underscore FA&amp;apos;s therapeutic potential in preventing and combating MetS.&lt;/Abstract>
	&lt;Access xmlns="http://purl.org/coar/access_right" 
    >
    &lt;/Access>
&lt;/Publication>
</dim:field>
</dim:dim>
</metadata></record></GetRecord></OAI-PMH>